Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Concizumab Prophylaxis in Hemophilia A or B with Inhibitors
KCT0004497Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of concizumab in hemophilia A, hemophilia B (HB), sponsored by Novo Nordisk. Started Dec 2019; status: active, not recruiting.
02
Drugs
concizumab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on KCT0004497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0004497.